Connect
← Return to Breast Cancer and complementary or integrative therapies
Discussion
Breast Cancer and complementary or integrative therapies
Breast Cancer | Last Active: Aug 5, 2023 | Replies (119)Comment receiving replies
Did you hear about doing this test before hormonal treatment?
The CYP2D6 enzyme catalyzes the main pathway for converting tamoxifen into its most potent metabolite, endoxifen, and together with other CYP enzymes, catalyzes the formation of 4-hydroxytamoxifen. Therefore, genetic variations in the CYP2D6 gene can influence tamoxifen metabolism....
Replies to "Did you hear about doing this test before hormonal treatment? The CYP2D6 enzyme catalyzes the main..."
Connect
Healthy women with poor CYP2D6 metabolism are less likely to respond to tamoxifen. Ultrarapid CYP2D6 metabolizers are at risk of having strong side-effects and discontinuing their tamoxifen therapy. CYP2D6 genotype might be considered in the future to guide tamoxifen prescription for breast cancer prevention...